Compare · AVTX vs NVO
AVTX vs NVO
Side-by-side comparison of Avalo Therapeutics Inc. (AVTX) and Novo Nordisk A/S (NVO): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both AVTX and NVO operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- NVO is the larger of the two at $191.82B, about 278.6x AVTX ($688.6M).
- Over the past year, AVTX is up 185.4% and NVO is down 43.1% - AVTX leads by 228.5 points.
- AVTX has been more active in the news (15 items in the past 4 weeks vs 7 for NVO).
- NVO has more recent analyst coverage (25 ratings vs 18 for AVTX).
- Company
- Avalo Therapeutics Inc.
- Novo Nordisk A/S
- Price
- $13.09-3.72%
- $42.94-1.84%
- Market cap
- $688.6M
- $191.82B
- 1M return
- -39.95%
- -6.14%
- 1Y return
- +185.39%
- -43.10%
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NASDAQ
- NYSE
- IPO
- 2015
- News (4w)
- 15
- 7
- Recent ratings
- 18
- 25
Novo Nordisk A/S
Novo Nordisk A/S, a healthcare company, engages in the research, development, manufacture, and marketing of pharmaceutical products worldwide. It operates in two segments, Diabetes and Obesity care, and Biopharm. The Diabetes and Obesity care segment provides products in the areas of insulins, GLP-1 and related delivery systems, oral antidiabetic products, obesity, and other chronic diseases. The Biopharmaceuticals segment offers products in the areas of haemophilia, growth disorders, and hormone replacement therapy. The company collaboration agreements with Lund University to develop treatment for Parkinson's diseases; and bluebird bio, Inc. to develop genome editing treatments for children and adult patients. Novo Nordisk A/S also has a research collaboration with Lumen Bioscience, Inc. to explore strategies for delivering oral biologics for cardiometabolic disease. The company was founded in 1923 and is headquartered in Bagsvaerd, Denmark.
Latest AVTX
- Amendment: SEC Form SCHEDULE 13G/A filed by Avalo Therapeutics Inc.
- SEC Form 4 filed by Director Lind Kevin Robert
- SEC Form 4 filed by Director Truex Samantha
- SEC Form 4 filed by Director Kaplan Gilla
- SEC Form 4 filed by Director Kantoff Aaron
- SEC Form 4 filed by Director Jain Rita
- SEC Form 4 filed by Director Heffernan Michael Thomas
- Chief Medical Officer Doyle Mittie exercised 679 shares at a strike of $8.04 and sold $10,864 worth of shares (679 units at $16.00) as part of a pre-agreed trading plan (SEC Form 4)
- Chief Executive Officer Neil Garry Arthur was granted 100,200 shares, increasing direct ownership by 111% to 190,314 units (SEC Form 4)
- Chief Legal Officer Varki Paul was granted 24,300 shares, increasing direct ownership by 669% to 27,934 units (SEC Form 4)
Latest NVO
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form SD filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- Peptide-Based Health Industry Positioned for Explosive Long-Term Growth Across Global Wellness Markets
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- The $59B Quiet Shift Reshaping How Patients Access Care
- Peptide Wellness Market Could Near $300 Billion as Consumer Demand Accelerates